BeOne Medicines Ltd
93 hedge funds and large institutions have $2.69B invested in BeOne Medicines Ltd in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 11 closing their positions.
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
15% more funds holding
Funds holding: 81 → 93 (+12)
3% more capital invested
Capital invested by funds: $2.61B → $2.69B (+$87.5M)
0.18% less ownership
Funds ownership: 4.84% → 4.66% (-0.18%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
49% less call options, than puts
Call options by funds: $4.01M | Put options by funds: $7.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$94.7M |
| 2 |
Temasek Holdings
Singapore
|
+$82.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.7M |
| 4 |
Morgan Stanley
New York
|
+$17.1M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$24.9M |
| 2 |
MAM
Myriad Asset Management
North Point,
Hong Kong
|
-$24.6M |
| 3 |
O
OppenheimerFunds
New York
|
-$12.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$6.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.15M |
ONC Hedge Fund Activity: Q4 2017 in Review
93 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2017, worth a combined $2.69B — up 3.4% from $2.61B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ONC positions and 11 closed out — a net gain of 12 holders — while 33 added to existing stakes and 26 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $94.7M. The largest seller was OrbiMed, cutting an estimated $24.9M.
- 93 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2017, up from 81 in Q3 2017.
- Funds reported $2.69B of BeOne Medicines Ltd stock for Q4 2017, up 3.4% quarter-over-quarter.
- 23 funds opened new BeOne Medicines Ltd positions in Q4 2017 and 11 closed out, a net change of +12 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2017 was Wellington Management Group, an estimated $94.7M added.
- The largest BeOne Medicines Ltd seller in Q4 2017 was OrbiMed, an estimated $24.9M sold.
Based on aggregated 13F filings for Q4 2017.